These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 37540382)

  • 1. Risk of incident cardiovascular events with disease-modifying anti-rheumatic drugs among adults with rheumatoid arthritis: a nested case-control study.
    Huang Y; Agarwal SK; Chatterjee S; Chen H; Johnson ML; Aparasu RR
    Clin Rheumatol; 2024 Jan; 43(1):103-116. PubMed ID: 37540382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world Comparative Effectiveness of Methotrexate-based Combinations for Rheumatoid Arthritis: A Retrospective Cohort Study.
    Huang Y; Agarwal SK; Chen H; Chatterjee S; Johnson ML; Aparasu RR
    Clin Ther; 2023 Sep; 45(9):e177-e186. PubMed ID: 37573225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors influencing prescribing the first add-on disease-modifying antirheumatic drugs in patients initiating methotrexate for rheumatoid arthritis.
    Huang Y; Chatterjee S; Agarwal SK; Chen H; Johnson ML; Aparasu RR
    Explor Res Clin Soc Pharm; 2023 Sep; 11():100296. PubMed ID: 37521021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA).
    Singh JA; Hossain A; Tanjong Ghogomu E; Mudano AS; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD012437. PubMed ID: 27855242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of treatment initiation with tumor necrosis factor-α inhibitors in patients with rheumatoid arthritis.
    Desai RJ; Rao JK; Hansen RA; Fang G; Maciejewski ML; Farley JF
    J Manag Care Spec Pharm; 2014 Nov; 20(11):1110-20. PubMed ID: 25351972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor necrosis factor-α inhibitor treatment and the risk of incident cardiovascular events in patients with early rheumatoid arthritis: a nested case-control study.
    Desai RJ; Rao JK; Hansen RA; Fang G; Maciejewski M; Farley J
    J Rheumatol; 2014 Nov; 41(11):2129-36. PubMed ID: 25086079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Efficacy of Novel DMARDs as Monotherapy and in Combination with Methotrexate in Rheumatoid Arthritis Patients with Inadequate Response to Conventional DMARDs: A Network Meta-Analysis.
    Buckley F; Finckh A; Huizinga TW; Dejonckheere F; Jansen JP
    J Manag Care Spec Pharm; 2015 May; 21(5):409-23. PubMed ID: 25943002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis.
    Katchamart W; Trudeau J; Phumethum V; Bombardier C
    Cochrane Database Syst Rev; 2010 Apr; 2010(4):CD008495. PubMed ID: 20393970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment Response to Tumor Necrosis Factor Inhibitors and Methotrexate Monotherapy in Adults With Juvenile Idiopathic Arthritis: Data From NOR-DMARD.
    Bardan I; Fagerli KM; Sexton J; Kvien TK; Bakland G; Mielnik P; Hu Y; Lien G; Flatø B; Molberg Ø; Kristianslund EK; Aga AB
    J Rheumatol; 2023 Apr; 50(4):538-547. PubMed ID: 36379571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subsequent Cardiovascular Events Among Patients With Rheumatoid Arthritis, Psoriatic Arthritis, or Psoriasis: Patterns of Disease-Modifying Antirheumatic Drug Treatment.
    Sparks JA; Lesperance T; Accortt NA; Solomon DH
    Arthritis Care Res (Hoboken); 2019 Apr; 71(4):512-520. PubMed ID: 29799667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment Patterns and Costs in Biologic DMARD-Naive Patients with Rheumatoid Arthritis Initiating Etanercept or Adalimumab with or Without Methotrexate.
    Tkacz J; Gharaibeh M; DeYoung KH; Wilson K; Collier D; Oko-Osi H
    J Manag Care Spec Pharm; 2020 Mar; 26(3):285-294. PubMed ID: 32105179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors associated with the initiation of biologic disease-modifying antirheumatic drugs in Texas Medicaid patients with rheumatoid arthritis.
    Kim G; Barner JC; Rascati K; Richards K
    J Manag Care Spec Pharm; 2015 May; 21(5):401-7. PubMed ID: 25943001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Examining Time to Initiation of Biologic Disease-modifying Antirheumatic Drugs and Medication Adherence and Persistence Among Texas Medicaid Recipients With Rheumatoid Arthritis.
    Kim G; Barner JC; Rascati K; Richards K
    Clin Ther; 2016 Mar; 38(3):646-54. PubMed ID: 26899313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.
    Singh JA; Hossain A; Tanjong Ghogomu E; Mudano AS; Maxwell LJ; Buchbinder R; Lopez-Olivo MA; Suarez-Almazor ME; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012591. PubMed ID: 28282491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Soliman MM; Ashcroft DM; Watson KD; Lunt M; Symmons DP; Hyrich KL;
    Ann Rheum Dis; 2011 Apr; 70(4):583-9. PubMed ID: 21330639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study.
    van Halm VP; Nurmohamed MT; Twisk JW; Dijkmans BA; Voskuyl AE
    Arthritis Res Ther; 2006; 8(5):R151. PubMed ID: 16984661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Risk of Cardiovascular Events Associated With Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis.
    Ozen G; Pedro S; Michaud K
    J Rheumatol; 2021 May; 48(5):648-655. PubMed ID: 32801134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of Treatment Change Among Patients with Rheumatoid Arthritis Treated with TNF Inhibitors as First-Line Biologic Agent in the USA: A Cohort Study from Longitudinal Electronic Health Records.
    Jin Y; Landon JE; Krueger W; Liede A; Desai RJ; Kim SC
    BioDrugs; 2022 Jul; 36(4):521-535. PubMed ID: 35771381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistence With Conventional Triple Therapy Versus a Tumor Necrosis Factor Inhibitor and Methotrexate in US Veterans With Rheumatoid Arthritis.
    Sauer BC; Teng CC; Tang D; Leng J; Curtis JR; Mikuls TR; Harrison DJ; Cannon GW
    Arthritis Care Res (Hoboken); 2017 Mar; 69(3):313-322. PubMed ID: 27273801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study.
    Gibofsky A; Palmer WR; Goldman JA; Lautzenheiser RL; Markenson JA; Weaver A; Schiff MH; Keystone EC; Paulus HE; Harrison MJ; Whitmore JB; Leff JA
    Curr Med Res Opin; 2006 Jan; 22(1):169-83. PubMed ID: 16393443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.